Get Started Today -
Call 1 800-770-9400
or click here for more info.

Watch How The
KOVANAZE® Dental Alliance
Can Build Your Practice

circles_600
DA_logo_800
Watch how KOVANAZE dental alliance can build your practice

As Powerful For Your Practice
As It Is For Your Patients

DA_logo_800

Get Started Today - Call 1 800-770-9400 or click here for more info.

circles_600

Watch How the KOVANAZE® Dental Alliance Can Build Your Practice

Watch how KOVANAZE dental alliance can build your practice

As Powerful For Your Practice As It Is For Your Patients

With the Kovanaze® Dental Alliance, you can attract new patients, engage existing customers and systematically grow your practice while, most importantly, providing your patients with the latest in dental innovation. The Kovanaze® Dental Alliance serves as your strategic partner in building your practice AND helping you to provide the utmost in empathetic patient care. When you become a member of the Kovanaze® Dental Alliance, you gain access to the most advanced digital customer acquisition platform available, as well a monthly supply of revolutionary no-needle Kovanaze® (tetracaine HCl and oxymetazoline HCl) Nasal Spray. While other marketing programs can cost hundreds, or even thousands more, yet deliver a fraction of the results, the Kovanaze® Dental Alliance leverages the power of iHeart media to ensure your marketing dollars achieve maximum reach and ROI. Each member of the Kovanaze® Dental Alliance receives personalized 15 second video and 30 second audio spots that are positioned on more than 300 websites and 150 mobile sites promoting your practice to 70% of consumers within your 3, 5 or 7 mile geofenced territory. You’ll secure 200,000 digital impressions each and every month, branding your services and touting your status as an official Kovanaze® provider. The Kovanaze® Dental Alliance also uses targeting and retargeting technology to ensure your practice stays top-of-mind for those most interested and in need of your services. Every month Kovanaze® Dental Alliance members receive a detailed customized report that highlights your total marketing reach and impact, finally allowing you to systematically and consistently track your marketing efforts. With the Kovanaze® Dental Alliance, you have the power to, quite literally, move the needle in your practice promotion. The Kovanaze® Dental Alliance… as powerful for your practice as it is for your patients.

Revolutionary Product Innovation Combined With State-of-the-Art Marketing Technology

KDA_circle@1x

Use State-of-the-Art Digital Technology to Connect with New and Existing Patients

tagline@1x
dig_media@1x

Personalized Digital Media

Audio and Video ad spots, customized for your practice are delivered directly to your target audience on their most trusty companion, their cell phone.

geo-fence@1x

Geofence Technology

Reach 70% of new and existing patients within miles of your practice. Target and retarget those most likely to want and need your services so you are top-of-mind when dental appointments need to be scheduled.

blueprint@1x

Mobile Blueprinting

Utilize actual consumer cell phone usage data to deliver your ads to your target demographic, maximizing your marketing and branding efforts.

Only The Kovanaze® Dental Alliance Can Deliver This Unbeatable Value Every Month

Enroll Today to Move the Needle in Your Practice Marketing!

Please enter your name.
Please enter a message.
DA_small@1x

Are you ready to take your practice promotion to the next level? Call or Email us your contact information to get started. We will send you all the information you need to put the KOVANAZE® Dental Alliance to work for you.

or call

1 800 770-9400

Copyright © 2016 St. Renatus. All Rights Reserved.

Important Safety Information

IMPORTANT SAFETY INFORMATION: KOVANAZE is indicated for regional anesthesia when performing a restorative procedure on Teeth 4-13 and A-J in adults and children who weigh 40 kg or more. Use in patients with uncontrolled hypertension or inadequately controlled active thyroid disease of any type is not advised. Tetracaine may cause methemoglobinemia, particularly in conjunction with methemoglobin-inducing agents. Use of KOVANAZE in patients with a history of congenital or idiopathic methemoglobinemia is not advised. Methemoglobinemia should be considered if central cyanosis unresponsive to oxygen therapy occurs, especially if methemoglobinemia-inducing agents have been used. Confirm diagnosis by measuring methemoglobin level with co-oximetry. Treat clinically significant symptoms of methemoglobinemia with a standard clinical regimen. Allergic or anaphylactic reactions can occur. If an allergic reaction occurs, seek emergency help immediately. KOVANAZE is contraindicated in patients with a history of allergy to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. Some clinical trial patients experienced an increase in blood pressure so blood pressure should be monitored. In addition, patients should be carefully monitored for dysphagia. KOVANAZE is not recommended for use in patients with a history of frequent nose bleeds. Concomitant use of monoamine oxidase inhibitors, nonselective beta adrenergic antagonist, or tricyclic antidepressants may cause hypertension and is not recommended. Discontinue use of oxymetazoline-containing products 24 hours prior to KOVANAZE administration. Avoid concomitant use of intranasal products. The most common adverse reactions to KOVANAZE occurring in >10% of patients include a runny nose, nasal congestion, nasal discomfort, sore throat, and watery eyes.

Click here for full Prescribing Information: Package Insert

IMPORTANT SAFETY INFORMATION: Use in patients with uncontrolled hypertension or inadequately controlled active thyroid disease of any type is not advised. Tetracaine may cause methemoglobinemia, particularly in conjunction with methemoglobin-inducing agents. Use of KOVANAZE in patients with a history of congenital or idiopathic methemoglobinemia is not advised. Methemoglobinemia should be considered if central cyanosis unresponsive to oxygen therapy occurs, especially if methemoglobinemia-inducing agents have been used. Confirm diagnosis by measuring methemoglobin level with co-oximetry. Treat clinically significant symptoms of methemoglobinemia with a standard clinical regimen. Allergic or anaphylactic reactions can occur. If an allergic reaction occurs, seek emergency help immediately. KOVANAZE is contraindicated in patients with a history of allergy to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. Some clinical trial patients experienced an increase in blood pressure so blood pressure should be monitored. In addition, patients should be carefully monitored for dysphagia. KOVANAZE is not recommended for use in patients with a history of frequent nose bleeds. Concomitant use of monoamine oxidase inhibitors, nonselective beta adrenergic antagonist, or tricyclic antidepressants may cause hypertension and is not recommended. Discontinue use of oxymetazoline-containing products 24 hours prior to KOVANAZE administration. Avoid concomitant use of intranasal products. The most common adverse reactions to KOVANAZE occurring in >10% of patients include a runny nose, nasal congestion, nasal discomfort, sore throat, and watery eyes.

Click here for full Prescribing Information: Package Insert